The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

The Centers for Disease Control and Prevention has made a dramatic about-face in the agency's position on the relationship ...

Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

A Centers for Disease Control and Prevention webpage that previously stated "Vaccines do not cause autism" has been changed ...

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.